The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Lacimen     diethyl2,6-dimethyl-4-[2- [(E)-2-[(2...

Synonyms: Lacipil, Lacirex, Viapres, Lacidipine, Lacidipino, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lacidipine


Psychiatry related information on Lacidipine

  • OBJECTIVE: The main objective of this study was to evaluate well-being and physical activity of 248 hypertensive patients, including 177 females, who had previously been included in the Latin-American Study on Lacidipine in Hypertension (LASTLHY) [5].

High impact information on Lacidipine


Chemical compound and disease context of Lacidipine


Biological context of Lacidipine


Anatomical context of Lacidipine

  • METHODS: In 8 patients with stable angina and moderate to severe stenosis of the left coronary artery, measurements of epicardial dimensions (quantitative angiography) and of coronary blood flow (Doppler guidewire) distal to a stenosis were performed at baseline and after 3 repeated intracoronary boluses of 12 microg of lacidipine [3].
  • Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine [19].
  • Between-group differences in favour of lacidipine for the primary efficacy variable (mean change in carotid artery intima-media thickness) did not reach statistical significance in the intent-to-treat population [20].
  • Moreover, lacidipine reduced circulating markers of oxidative stress including plasma and low-density lipoprotein (LDL) hydroperoxides, the susceptibility of LDL to Cu2+-induced oxidation and the reactive oxygen species generated from human umbilical vein endothelial cells after incubation with LDL derived from plasma of the patients [21].
  • Thus, lacidipine reduced blood pressure and free radicals, avoiding the oxidative damage to endothelium [10].

Associations of Lacidipine with other chemical compounds


Gene context of Lacidipine

  • The lowest IC50, i.e. the concentration determining the 50% reduction of ICAM-1, VCAM-1 and E-selectin expression was obtained with lacidipine for all the adhesion molecules considered (P < 0.01) [24].
  • Finally, peritoneal macrophages, obtained from mice treated with lacidipine, showed a reduced secretion of MMP-9 [25].
  • Lacidipine reduced also the secretion of the tissue inhibitor of metalloproteinase-1 (TIMP-1); however we observed an overall reduction of the gelatinolytic activity of the cells [25].
  • Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats [13].
  • 4. The maximum binding capacity (Bmax) and the dissociation constant (KD) of [125I]-ET-1 binding and the relative proportion of low- and high-affinity binding sites for ET-3 were not significantly affected by salt loading or lacidipine treatment in SHRSP [13].

Analytical, diagnostic and therapeutic context of Lacidipine


  1. Angiotensin-converting enzyme inhibition prevents glomerular-tubule disconnection and atrophy in passive Heymann nephritis, an effect not observed with a calcium antagonist. Benigni, A., Gagliardini, E., Remuzzi, A., Corna, D., Remuzzi, G. Am. J. Pathol. (2001) [Pubmed]
  2. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). Zanchetti, A., Bond, M.G., Hennig, M., Tang, R., Hollweck, R., Mancia, G., Eckes, L., Micheli, D. J. Hypertens. (2004) [Pubmed]
  3. Coronary artery vasomotion and post-stenotic coronary artery blood flow after intracoronary lacidipine in patients with ischaemic heart disease: a pilot study. Vassanelli, C., Menegatti, G., Marini, A., Beltrame, F., Molinari, J., Cemin, R. Drugs (1999) [Pubmed]
  4. Impact of calcium antagonists on the cardiovascular system: experience with lacidipine. Kuschnir, E. Drugs (1999) [Pubmed]
  5. Semipersonalized psychological evaluation of quality of life in hypertensive patients during a trial with two calcium antagonists: a multicenter Latin-American Study (LASTLHY). Velasco, M., Lezama, E., Hernández-Hernández, R., Armas-Hernández, M.J., Armas-Padilla, M.C., Alcocer, L. International journal of clinical pharmacology and therapeutics. (2001) [Pubmed]
  6. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Taddei, S., Virdis, A., Ghiadoni, L., Uleri, S., Magagna, A., Salvetti, A. Hypertension (1997) [Pubmed]
  7. Calcium blocker lacidipine and carotid arteriolar vasodilation in healthy volunteers. Safar, M., Bons, J., Georges, D., Cournot, A., Duchier, J. Clin. Pharmacol. Ther. (1989) [Pubmed]
  8. Quality control of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis. Tang, R., Hennig, M., Bond, M.G., Hollweck, R., Mancia, G., Zanchetti, A. J. Hypertens. (2005) [Pubmed]
  9. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Kuypers, D.R., Neumayer, H.H., Fritsche, L., Budde, K., Rodicio, J.L., Vanrenterghem, Y. Transplantation (2004) [Pubmed]
  10. Changes in iNOS activity, oxidative stress and melatonin levels in hypertensive patients treated with lacidipine. Escames, G., Khaldy, H., León, J., González, L., Acuña-Castroviejo, D. J. Hypertens. (2004) [Pubmed]
  11. Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly. Wing, L.M., Arnolda, L.F., Harvey, P.J., Upton, J., Molloy, D., Bune, A.J., Chalmers, J.P. J. Hypertens. (1997) [Pubmed]
  12. Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats. Kyselovic, J., Krenek, P., Wibo, M., Godfraind, T. Br. J. Pharmacol. (2001) [Pubmed]
  13. Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats. Feron, O., Salomone, S., Godfraind, T. Br. J. Pharmacol. (1996) [Pubmed]
  14. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Su, J., Georgiades, A., Wu, R., Thulin, T., de Faire, U., Frostegård, J. Atherosclerosis (2006) [Pubmed]
  15. Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension and diabetes. Rumble, J.R., Doyle, A.E., Cooper, M.E. Am. J. Hypertens. (1995) [Pubmed]
  16. Prevention of salt-dependent cardiac remodeling and enhanced gene expression in stroke-prone hypertensive rats by the long-acting calcium channel blocker lacidipine. Kyselovic, J., Morel, N., Wibo, M., Godfraind, T. J. Hypertens. (1998) [Pubmed]
  17. Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. Da Ros, L., Squassante, L., Milleri, S. Clinical pharmacokinetics. (2003) [Pubmed]
  18. Relationship between mechanical properties of the carotid artery wall and baroreflex function in acutely treated hypertensive patients. Carretta, R., Bardelli, M., Cominotto, F., Ussi, D., Fazio, M., Fabris, B., Fischetti, F., Campanacci, L. J. Hypertens. (1996) [Pubmed]
  19. Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine. Cominacini, L., Garbin, U., Pasini, A.F., Davoli, A., Campagnola, M., Pastorino, A.M., Gaviraghi, G., Lo Cascio, V. J. Hypertens. (1998) [Pubmed]
  20. Lacidipine: a review of its use in the management of hypertension. McCormack, P.L., Wagstaff, A.J. Drugs (2003) [Pubmed]
  21. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. Taddei, S., Virdis, A., Ghiadoni, L., Magagna, A., Pasini, A.F., Garbin, U., Cominacini, L., Salvetti, A. J. Hypertens. (2001) [Pubmed]
  22. Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). Giannattasio, C., Failla, M., Hennig, M., Hollweck, R., Laurent, S., Mallion, J.M., Reid, J., Safar, M., Bond, G., Zanchetti, A., Mancia, G. J. Hypertens. (2005) [Pubmed]
  23. Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits. Soma, M.R., Donetti, E., Seregni, R., Barberi, L., Fumagalli, R., Paoletti, R., Catapano, A.L. Br. J. Pharmacol. (1996) [Pubmed]
  24. Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells. Cominacini, L., Pasini, A.F., Pastorino, A.M., Garbin, U., Davoli, A., Rigoni, A., Campagnola, M., Tosetti, M.L., Rossato, P., Gaviraghi, G. J. Hypertens. (1999) [Pubmed]
  25. Lacidipine [correction of Lalsoacidipine] modulates the secretion of matrix metalloproteinase-9 by human macrophages. Bellosta, S., Canavesi, M., Favari, E., Cominacini, L., Gaviraghi, G., Fumagalli, R., Paoletti, R., Bernini, F. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  26. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. Cristofori, P., Lanzoni, A., Quartaroli, M., Pastorino, A.M., Zancanaro, C., Cominacini, L., Gaviraghi, G., Turton, J. J. Hypertens. (2000) [Pubmed]
  27. Structural changes of small resistance arteries in spontaneously hypertensive rats after treatment with various doses of lacidipine. Porteri, E., Rizzoni, D., Castellano, M., Bettoni, G., Muiesan, M.L., Salvetti, M., Quartaroli, M., Gaviraghi, G., Rosei, E.A. J. Hypertens. (1997) [Pubmed]
  28. Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension. Lee, C.R., Bryson, H.M. Drugs (1994) [Pubmed]
WikiGenes - Universities